| 摘要 |
1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, with positive effect by glycemic control without observable unfavourable effects, which method comprises administering 2 to 12 mg daily 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound I) or a pharmaceutically acceptable salt thereof , and sulfonyl urea. 2. A method according to Claim 1, wherein the c is glibenclamide, glipizide, gliclazide, glimepiride, tolazamide or tolbutamide. 3. A method according to any one of Claims 1 or 2, wherein the sulfonyl urea is glimepiride. 4. A method according to any one of Claims 1 to 4, which comprises the administration of 2 to 4, or 4 to 8 or 8 to 12 mg of Compound (I). 5. A method according to any one of Claims 1 to 4, which comprises the administration of 2 to 4 mg of Compound (I). 6. A method according to any one of Claims 1 to 4, which comprises the administration of 4 to 8 mg of Compound (I). 7. A method according to any one of Claims 1 to 4, which comprises the administration of 8 to 12 mg of Compound (I). 8. A method according to any one of Claims 1 to 4, which comprises the administration of 2 mg of Compound (I). 9. A method according to any one of Claims 1 to 4, which comprises the administration of 4 mg of Compound (I). 10. A method according to any one of Claims 1 to 4, which comprises the administration of 8 mg of Compound (I). |
